Drugmaker Torrent Pharmaceuticals Ltdon Friday (October 23) reported a 9.6% year-on-year (YoY) decline in net profit to ₹534 crore for the September quarter, compared with ₹591 crore a year ago.
Net profit also missed the poll estimate of ₹544.3 crore. Revenue rose 50.8% YoY to ₹4,979 crore from ₹3,302 crore, beating the CNBC-TV18 poll estimate of ₹4,905.6 crore.
Earnings before interest, tax, depreciation and amortisation (EBITDA) increased 54.1% YoY to ₹1,583 crore from ₹1,027 crore, but missed the CNBC-TV18 poll estimate of ₹1,624.7 crore.
ALSO READ | Torrent Pharma Q4 net profit tanks despite jump in revenue; declares ₹9 dividend
The EBITDA margin expanded to 32.33% from 31.6% a yeTorrent Pharma Q2 Results: Net profit declines despite 51% revenue growth; misses estimatesar ago, compared with the poll estimate of 33%.
India Business Revenue
Torrent Pharmaceuticals’ India revenue increased 20% YoY to ₹2,181 crore in Q2 FY27, compared with growth of 12% in the Indian Pharmaceutical Market (IPM), according to the PharmaTrac dataset.
The company’s generic (Gx) semaglutide products recorded a combined market share of 32% during the quarter across oral and injectable formulations, as per PharmaTrac. For the first half of FY27, India revenue rose 19% to ₹4,338 crore.
Brazil Revenue
Revenue from Brazil increased 38% YoY to ₹440 crore. In constant currency terms, revenue rose 20% to 236 million Brazilian reais.
ALSO READ | Ruby Mills sells 33rd-floor commercial space at The Ruby to Torrent Pharma for ₹124 crore
According to IQVIA, Torrent’s growth in Brazil stood at 26% during the quarter, compared with market growth of 6%, aided by the performance of leading brands and new launches. The company had 53 products under review with Brazil’s National Health Surveillance Agency (ANVISA).
For H1 FY27, Brazil revenue increased 34% to ₹717 crore. Constant-currency revenue rose 13% to 383 million Brazilian reais.
US Revenue
Revenue from the United States increased 24% YoY to ₹417 crore in Q2 FY27. In constant currency terms, revenue rose 13% to $44 million, driven by new launches achieving targeted market share. For H1 FY27, US revenue increased 29% to ₹835 crore, while constant-currency revenue rose 17% to $88 million.
Germany Revenue
Germany revenue declined 7% YoY to ₹283 crore in Q2 FY27. In constant-currency terms, revenue fell 13% to 26 million euros.
ALSO READ | Torrent Pharma Q3 net profit surges 26% on strong revenue growth, declares ₹29 dividend
The company said growth continued to be affected by supply disruptions at a third-party supplier and the loss of certain high-volume tenders. For H1 FY27, Germany revenue declined 2% to ₹601 crore, while constant-currency revenue fell 11% to 55 million euros.
JB Business
In the JB business, India prescription revenue, excluding trade generics and contrast media, increased 7% YoY to ₹597 crore in Q2 FY27. For H1 FY27, revenue rose 10% to ₹1,252 crore.
International business revenue, comprising the US, emerging markets and contract development and manufacturing organisation (CDMO) operations, declined 7% to ₹406 crore during the quarter. For H1 FY27, revenue increased 2% to ₹874 crore.
Following the merger, effective July 8, 2026, integration of the India business, optimisation of the global business network, and alignment of manufacturing and quality management systems had a temporary impact on revenue during Q2 FY27.
ALSO READ | Torrent Pharma shares gain 4% after steady Q3; Street positive on JB merger benefits
Shares of Torrent Pharmaceuticals Ltd ended at ₹4,482.00, down by ₹128.15, or 2.78%, on the BSE.